Burcak Cavnar Helvaci

Dr. Burcak Cavnar Helvaci

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
BHBurcak Cavnar Helvaci
Burcak Cavnar Helvaci
SHSema Hepsen
Sema Hepsen
BCBurcu Candemir
Burcu Candemir
OBOgulcan Boz
Ogulcan Boz
HDHalil Durantas
Halil Durantas
ECErman Cakal
Erman Cakal

21 April 2023 in Hormones
Verified
Journal Article
Closed access
PDF file
BHBurcak Cavnar Helvaci
Burcak Cavnar Helvaci
MYMehmet Muhittin Yalçın
Mehmet Muhittin Yalçın
ŞYŞehnaz Neslihan Gürz Yalcın
Şehnaz Neslihan Gürz Yalcın
EAEmre Arslan
Emre Arslan
AAAlev Eroğlu Altinova
Alev Eroğlu Altinova
FTFüsun Baloş Törüner
Füsun Baloş Törüner

16 December 2023 in Hormones
Verified
Journal Article
Closed access
PDF file
BHBurcak Cavnar Helvaci
Burcak Cavnar Helvaci
DODidem Ozdemir
Didem Ozdemir
KTKubra Turan
Kubra Turan
CKCaglar Keskin
Caglar Keskin
NINarin Nasiroglu İmGa
Narin Nasiroglu İmGa
BCBekir Cakir
Bekir Cakir

6 August 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
BHBurcak Cavnar Helvaci
Burcak Cavnar Helvaci
BEBeril Turan Erdogan
Beril Turan Erdogan
DODidem Ozdemir
Didem Ozdemir
OTOya Topaloglu
Oya Topaloglu
BCBekir Cakir
Bekir Cakir
SUMMARY Euglycemic diabetic ketoacidosis (DKA) is a rare complication of diabetes mellitus (DM) characterized by metabolic acidosis, ketosis, and blood glucose levels < 250 mg/dL. The prevalence of euglycemic DKA is increasing with the popularity of ketogenic (low-carbohydrate) diets. We present herein the case of a patient with newly diagnosed type 1 DM who developed euglycemic DKA following a ketogenic diet. A 22-year-old woman presented to the emergency department with malaise, fatigue, nausea, and vomiting. She had no family history

24 March 2024 in Endocrine Practice
Verified
Journal Article
Closed access
BHBurcak Cavnar Helvaci
Burcak Cavnar Helvaci
SPSefika Burcak Polat
Sefika Burcak Polat
BBBelma Tural Balsak
Belma Tural Balsak
NBNagihan Bestepe
Nagihan Bestepe
OTOya Topaloglu
Oya Topaloglu
BCBekir Cakir
Bekir Cakir

8 June 2025 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
BHBurcak Cavnar Helvaci
Burcak Cavnar Helvaci
ATAbbas Ali Tam
Abbas Ali Tam
BEBeril Turan Erdogan
Beril Turan Erdogan
SFSevgül Faki
Sevgül Faki
NSNeslihan Cuhaci Seyrek
Neslihan Cuhaci Seyrek
BCBekir Cakir
Bekir Cakir
Introduction: Non-alcoholic fatty liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD), represents a significant health burden worldwide. Patients with Cushing's syndrome (CS), a condition characterized by excessive cortisol production, may be at an elevated risk for MASLD due to associated metabolic disturbances.Material and methods: This study aimed to evaluate the predictive value of the hepatic steatosis index (HSI) in diagnosing MASLD in patients with CS. 101 endogenous CS patients were included, and hepatosteatosis was assessed using ultrasonography. HSI scores were calculated, and associations with clinical and biochemical parameters were analyzed.Results: Hepatosteatosis was observed in 62.4% of CS patients, with all these individuals meeting the criteria for MASLD. The HSI demonstrated hepatosteatosis with high sensitivity (92.1%) and specificity (78.9%) compared to ultrasonography. Factors significantly correlated with hepatosteatosis included higher BMI, diabetes, hypertension, and hyperlipidemia. There was no correlation with basal morning cortisol, 24-hour urinary free cortisol, low-dose dexamethasone suppression tests, or the etiology of CS.Conclusions: Our study represents a pioneering effort to explore MASLD in patients with endogenous CS by evaluating the HSI as a diagnostic tool. Utilizing the HSI, we demonstrated high sensitivity and specificity in diagnosing hepatosteatosis, emphasizing its potential as a valuable non-invasive tool in this population. Furthermore, our study fills a significant gap in the literature by being the first to investigate the predictive power of HSI for MASLD diagnosis, specifically in CS patients. Integrating these findings into clinical practice could enhance the early detection and management of MASLD in endogenous CS, ultimately improving patient outcomes.